Clinical trials: Thyroid Cancer Patients
Cancer
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer
This is a 2-arm randomized controlled study comparing how effective two therapeutic digital software devices are at improving anxiety and other indicators of psychological and physical health in patients with cancer.
- Trial name
- RESTORE (NCT05227898)
- Testing
- Device: Attune™, Device: Cerena™
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Blue Note Therapeutics
Medullary Thyroid Cancer
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition.
- Trial name
- NCT06079723
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Neoplasms
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant…
- Trial name
- NCT01286753
- Testing
- Vemurafenib
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Total Thyroidectomy, Near-total Thyroidectomy
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total…
- Trial name
- NCT03276988
- Testing
- Period 1 GX-30, Period 2 THYROGEN®, Period 1 THYROGEN®, Period 2 GX-30
- Where
- 5 sites in South Korea
- Volunteers
- 8 people
- Sponsor
- Genexine, Inc.
Differentiated Thyroid Cancer
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake Effects For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients
- Trial name
- NCT04137185
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Differentiated Thyroid Cancer
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
This is A non-blinded trial. Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration.
- Trial name
- NCT04971473
- Testing
- rhTSH
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thyroid Cancer
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with…
- Trial name
- NCT00124527
- Testing
- Irofulven + capecitabine
- Where
- 10 sites in United States, Argentina and 4 more
- Volunteers
- 35 people
- Sponsor
- Eisai Inc.
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Renal Cell Carcinoma, Hepatocellular Carcinoma
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma
- Trial name
- NCT03776123
- Where
- 47 sites in South Korea
- Volunteers
- 347 people
- Sponsor
- Ipsen
Heart Diseases, CKD
Nurse-led Medication Self-management Intervention in the Improvement of Medication Adherence
Back ground \& Aims Adult patients suffering from multimorbidity are at high risk of medication non-adherence. It has been well established that self-management support is an effective strategy to enhance medication adherence for…
- Conditions
- Heart Diseases, CKD, Diabetes, Cancer
- Trial name
- NCT05645653
- Testing
- Motivational tteaching
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Cancer, BRAF V600 Mutation
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF…
- Conditions
- Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer
- Trial name
- ENHANCE (NCT05275374)
- Testing
- XP-102, Trametinib
- Volunteers
- 221 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Differentiated Thyroid Carcinoma (DTC)
Post-Marketing Surveillance of Lenvima in Korean Patients
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
- Trial name
- NCT02764554
- Where
- 32 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Eisai Korea Inc.
Anaplastic Thyroid Cancer
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
- Trial name
- NCT05819593
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Tumor
A Phase II Study of Anlotinib in MTC Patients
Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
- Trial name
- ALTN/MTC (NCT01874873)
- Testing
- Anlotinib
- Where
- 10 sites in China
- Volunteers
- 58 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation